Synergies Explained: Why the Market Pays for Cost Cuts and Discounts Revenue Synergies to Zero — the Premium Justification, the Cost-to-Achieve, and the Majority That Never Arrive
10 min read
- Synergies split into two buckets the market treats as opposites. Cost synergies — headcount, real estate, procurement, duplicate systems — are subtraction: they remove a cost that already exists and can be measured, so the market largely credits them. Revenue synergies — cross-sell, pricing power, new geographies — are addition: unproven, dependent on customer behaviour, and discounted toward zero
- Every pound of run-rate synergy carries a cash price. The cost-to-achieve — severance, systems integration, restructuring, advisory — typically runs on the order of one to two times the annual run-rate saving (approximate, deal-specific) and is paid up front, before a single pound of saving lands. The press release rarely leads with it
- The valuation test is not the synergy headline; it is whether the present value of net synergies exceeds the control premium. Premiums run roughly 20–35% over the unaffected price — if net synergies do not clear that, the acquirer is handing value to the target's shareholders, not creating it (see accretion/dilution)
- The evidence is unkind. Studies have for decades put the share of deals that fail to create value at roughly 60–80%, with revenue synergies the worst offenders. The market prices the skepticism in — which is why an acquirer's shares fall on announcement more often than they rise
Two Buckets the Market Treats as Opposites: Cost Synergies Get Credited, Revenue Synergies Get Discounted to Zero
A synergy is a single claim: that the combined company is worth more than the two businesses standing apart. Every acquisition premium rests on it, because a buyer paying 30% over the market price has to believe it can extract more than 30% of incremental value from owning the asset. The mistake students make is treating "synergies" as one number. The market does not.
It splits them into two buckets and prices them on opposite sides of a line. Cost synergies are subtraction — they remove a duplicated expense that already sits in the accounts, so they are evidenced, quantifiable, and largely within the buyer's control. Revenue synergies are addition — they assume customers will buy more, or pay more, after the deal — so they are a forecast about other people's behaviour. The first is credited; the second is discounted toward zero. Understanding why is the whole topic.
Cost Synergies Are Subtraction: Headcount, Real Estate, Procurement, Duplicate Systems
Cost synergies are reliable for a structural reason — they eliminate a cost that already exists, and the buyer controls the lever. Two head offices become one. Overlapping sales teams, finance functions and back-office headcount are rationalised. Two ERP systems collapse to one. Combined purchasing volume extracts better terms from suppliers. None of this depends on a customer doing anything; it depends on the acquirer executing a plan it can write on day one.
That control is why the market gives cost synergies most of the benefit of the doubt, and why they are the bucket buyers most often deliver. It is not a free pass: even here, a meaningful minority of deals — roughly a quarter, on the studies, though the figure moves by sector — fall materially short, usually because integration drags, retention deals soften the headcount cuts, or the savings are competed away in price. But the base rate is high enough that a disciplined buyer can underwrite cost synergies and a disciplined market can capitalise them. Revenue synergies are the opposite case.
Revenue Synergies Are Addition: The Line the Market Refuses to Pay For
Revenue synergies are the seductive half of the pitch — cross-sell the acquirer's product into the target's base, raise prices with reduced competition, push both into new geographies. They are also the half almost nobody delivers in full. The reason is that revenue synergies are a bet on customer behaviour the buyer does not control: the cross-sell assumes the target's customers want the acquirer's product, the pricing assumes they will not walk, and both assume two sales forces will cooperate rather than defend their own accounts.
The empirical record matches the skepticism. On McKinsey's work, companies capture on average only around 60% of the revenue synergies they project (approximate), and the shortfall is worst precisely where the deal thesis leaned hardest on cross-selling. So the market applies its own haircut: it credits cost synergies, and it values announced revenue synergies at close to nothing until they show up in actual results.
The Cost to Achieve: Every Pound of Run-Rate Synergy Has a Cash Price Paid Up Front
The headline synergy figure is a steady-state, full-year, run-rate number — what the combined business will save once everything is done. Getting there costs cash, and that cost is the line the press release buries. Severance to remove the headcount, the write-off and rebuild to merge two systems, lease-break costs to vacate the duplicate property, retention packages to keep the people who survive the cut, and the advisory bill on top.
As a rule of thumb, the one-off cost-to-achieve runs on the order of one to two times the annual run-rate synergy (approximate, and highly deal-specific) — and unlike the saving, it is paid almost entirely up front, before a pound of benefit lands. That timing is the trap. A deal that announces £100m of run-rate cost synergies may spend £100–200m of cash to capture them, in year one, against a saving that only reaches full run-rate in year three. Ignore the cost-to-achieve and a synergy looks like free money; include it and the first two years are a cash outflow.
Phasing: Synergies Land in Years 2–3, the Premium Is Wired on Day One
The second trap is timing, and it is the one a discounted valuation punishes hardest. The premium is paid in full at completion; the synergies arrive on a curve. A clean integration might realise a third of run-rate cost synergies in year one, two-thirds by year two, and full run-rate by year three — with revenue synergies, if they come at all, lagging further still. The present value of a benefit that ramps over three years, net of a cost paid on day one, is a great deal smaller than the run-rate headline suggests.
What a Synergy Is Worth: Capitalise the Net Run-Rate, Then Compare It to the Premium
This is the calculation that turns a press-release number into a verdict. The value created by a synergy is, roughly, the after-tax run-rate saving capitalised — either divided by the cost of capital for a perpetual saving, or, more conservatively, multiplied by the EBITDA multiple the market applies to the combined business — less the present value of the cost-to-achieve. Set that net synergy value against the premium paid, which is the offer price minus the unaffected price, across the target's shares. If net synergies clear the premium, the buyer keeps the surplus; if they do not, the premium is a transfer to the target's selling shareholders.
A worked sketch makes the asymmetry concrete. Take a target with a £1bn unaffected equity value, bought at a 30% premium — £300m handed over before any value is created.
| Component | Figure | Read |
|---|---|---|
| Premium paid (30% over £1bn) | £300m | The hurdle the synergies must clear |
| Run-rate cost synergy (pre-tax) | £60m | Subtraction — duplicated cost the buyer controls |
| After-tax, at 25% | £45m | The saving the equity actually keeps |
| Capitalised at a 10x multiple | £450m | The gross value of the cost bucket |
| Less cost-to-achieve (~1.5x run-rate) | (£90m) | Cash spent up front to capture it |
| Net value from cost synergies | ~£360m | Clears the £300m premium — on cost alone |
| Announced revenue synergy | £40m | The market values this near zero until realised |
The point of the sketch is not the precision of any line — the figures are illustrative — but the shape it exposes. A deal can be justified on credible cost synergies alone, with revenue synergies as genuine upside the buyer is not paying for. Reverse it — a thin cost bucket and a premium underwritten on cross-sell — and the same arithmetic says the buyer is overpaying. That is the difference the merger model has to surface.
Synergies in the Merger Model: The Line That Flips Dilution to Accretion
In an accretion/dilution analysis, synergies are the swing factor. The combined company's pro-forma earnings are the two income statements stacked, plus after-tax synergies, less the new financing cost of the deal. A deal that looks dilutive on standalone earnings frequently turns accretive once synergies are layered in — which is exactly why the synergy assumption is the first thing a sharp interviewer attacks.
The tell of a candidate who has built a real model rather than memorised one is how they treat that line. They phase the synergies rather than switching them on at full run-rate in year one, they net the cost-to-achieve against the early years, and they flag that revenue synergies are the soft assumption. "The deal is accretive" is a weak answer; "the deal is accretive from year two once cost synergies ramp, and it relies on £X of synergies — strip those out and it is dilutive, which tells you how much of the premium is riding on execution" is the answer that ends the line of questioning.
The Evidence: Most Synergy Targets Are Missed, and the Market Prices the Skepticism In
The base rates are the part of this topic students never see and practitioners never forget. Decades of work from the strategy houses and academics have put the share of M&A that fails to create value for the acquirer at roughly 60–80% (approximate; definitions of "failure" vary). Revenue synergies are the consistent culprit — over-projected, slow to arrive, and frequently competed away. Cost synergies hold up better, but even they are missed materially in a meaningful minority of deals.
This is why an acquirer's stock so often drops the day a deal is announced. The market is doing the calculation above in real time: it takes the premium as certain, credits the cost synergies in part, values the revenue synergies near zero, and concludes the buyer has probably overpaid. The drop is not a verdict on the strategy — it is the present value of skepticism, applied to a synergy number the market has learned to distrust.
The Verdict: Synergies Justify the Premium — They Do Not Vindicate It
Synergies are best understood as the argument a buyer makes for paying more than the market does. That argument can be sound or it can be a rationalisation, and the line between them is not the size of the headline number but its composition. A premium underwritten on cost synergies — duplicated functions the buyer can remove, net of the cash it costs to remove them, capitalised against the multiple the market actually pays — is a defensible bet. A premium underwritten on revenue synergies is a hope dressed as a model.
The judgement an interviewer is testing is whether you can take a synergy number apart: separate the credited bucket from the discounted one, subtract the cost-to-achieve the press release omitted, phase the benefit against a premium paid on day one, and say whether the present value clears the price. Anyone can recite "cost and revenue synergies." Reading which one the deal is really resting on — and pricing the difference — is the part that sounds like someone who has stress-tested a live model.
Careers: An Associate Stress-Tests the Synergy Number
On a live deal the synergy line is where a junior earns or loses the senior banker's trust. The associate building the merger model is not asked to invent the synergies — those come from management and the commercial team — but to pressure-test them: phase them realistically, attach the cost-to-achieve, run the accretion with and without the soft assumptions, and show the partner how much of the premium is riding on each bucket. The deliverable is a sensitivity, not a point estimate.
The skill that compounds is reading the synergy case the way the market will. An associate who can tell a partner "the cost synergies carry the deal, the revenue line is upside we are not paying for" — or the opposite, "strip the cross-sell and this is dilutive and we are overpaying" — is doing the analytical work the deal turns on, the same instinct that separates a real quality-of-earnings review from a checklist and a genuine value-creation bridge from a wish list.
Take Your Preparation Further
Synergies sit inside the M&A model and the M&A process, so read them alongside the pieces that build both. Start with EPS accretion/dilution for where the synergy line actually lands, and the M&A process from mandate to close for where the number gets negotiated. For why precedent transactions sit above trading comps, see comps and precedents — the gap is the control premium and the synergies a strategic buyer expects to capture. For the sponsor's version of the same discipline, read buy-and-build, where integration synergies are the difference between a platform multiple and a conglomerate discount, and the value-creation bridge that decomposes where returns really come from.
For the full M&A process on one page — stages, parties, and the documents at each step — download our free M&A Process Cheat Sheet, and to build the synergy line into a working accretion/dilution model yourself, use the Merger & Accretion/Dilution Model.
Ready for personalised feedback? Book a 1-on-1 mentoring session with an experienced IB/PE professional.